37th EDRN Steering Committee Meeting/Prostate and Urological Cancers Collaborative Group Meeting Draft Agenda

Tuesday, October 19, 2021

10:00 a.m. – 5:00 p.m. Eastern Time

Chair: O. John Semmes, PhD, Eastern Virginia Medical School

Co-Chair: Martin Sanda, MD, Emory University School of Medicine

NCI Program Directors:   Jacob Kagan, MSc, PhD, and Richard Mazurchuk, PhD, National Cancer Institute



10:00 a.m. – 10:05 a.m.


o   O. John Semmes, PhD, East Virginia Medical School

o   Martin Sanda, MD, Emory University School of Medicine



10:05 a.m. – 10:10 a.m.

NCI Updates

o   Jacob Kagan, MSc, PhD National Cancer Institute

o   Richard Mazurchuk, PhD, National Cancer Institute



10:10 a.m. – 10:25 a.m.

01: Report from the Advocates  

Merel Grey Nissenberg, Esq., President, California Prostate Cancer Coalition



10:25 a.m. – 11:15 a.m.

Team Projects and Projects (Supported with CORE Funds)


o   What was accomplished and what remains to be done

o   Feasibility of completion

o   Lessons learned

o   Recommendations for improvements



10:25 a.m. – 10:45 a.m.

02: P-MRI Study Update


John T. Wei, MD, University of Michigan

10:45 a.m. – 10:50 a.m.




10:50 a.m. – 11:10 a.m.

03: The Prostate Upgrading Study

o     Phase 1: Robin Leach, PhD, The University of Texas Health Science Center San Antonio 

o     Phase 2: Paul Boutros, PhD, MBA, Cancer Data Science, University of California, Los Angeles

11:10 a.m. – 11:15 a.m.



11:15 a.m.  – 11:25 a.m.




11:25 a.m. – 2:50 p.m.

Updates on GU Collaborative Group’s Studies



11:25 a.m. – 11:45 a.m.  

04: Evolution of MyProstateScore (MPS): Urine transcriptomic analyses to detect aggressive prostate cancer

Arul Chinnaiyan MD, PhD, University of Michigan


11:45 a.m. – 11:50 a.m.




11:50 a.m. – 12:10 p.m.

05: Glycoprotein Marker Panels for Aggressive Prostate Cancer Detection

Hui Zhang, PhD, Johns Hopkins University School of Medicine



12:10 p.m. – 12:15 p.m.




12:15 p.m. – 12:35 p.m.

06: Proteomics Approaches to Detect Aggressive Prostate Cancers

Thomas Kislinger, MSc, PhD, University of Toronto

12:35 p.m. – 12:40 p.m.




12:40 p.m. – 1:00 p.m.

07: Combining Serum Phi and Urine PCA3/T2Erg to Refine Patient Selection for Prostate Biopsy

Martin Sanda, MD, Emory University

1:00 p.m. – 1:05 p.m.




1:05 p.m. – 1:35 p.m.

Lunch Break


1:35 p.m. – 1:55 p.m.

08: Development of a  Panel of Biomarkers for Aggressive Prostate Cancer

Daniel W. Chan, PhD, Johns Hopkins University

1:55 p.m. – 2:00 p.m.




2:00 p.m. – 2:20 p.m.

09: Towards Early Prediction of Prostate Cancer Progression Applying Advanced Mass Spectrometry Technologies

Tao Liu PhD Pacific Northwest National Laboratory

2:20 p.m. – 2:25 p.m.




2:25 p.m. – 2:45 p.m

10: CPDR-EDRN BRL: Dynamic Progress of Collaborative Biomarker Projects

Gyorgy Petrovics, PhD, Center for Prostate Disease Research (CPDR)


2:45 p.m. – 2:50 p.m.



2:50 p.m. – 3:00 p.m.




3:00 p.m. – 4:00 p.m.

Discussion of Prostate Cancer Clinical Utility Study

Moderator: Martin Sanda, MD, Emory University




o   Yingye Zheng, PhD, Fred Hutchinson Cancer Research Center

o   Martin Sanda, MD, Emory University

o   Alan W. Partin, MD, PhD, Johns Hopkins University

o   Jeffrey Tosoian, MD, MPH, Vanderbilt University



4:00 p.m. – 5:00 p.m.

Summary and Open Discussion of the Current and Future Directions of the GU Collaborative Group

O. John Semmes, PhD, East Virginia Medical School


5:00 p.m.

Adjourn for the Day

Version 5.1.1